Drugs / UBT251
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07710729 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07710768 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT07668388 | Jun 2026 → Oct 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07395687 | Feb 2026 → Jan 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07145151 | Sep 2025 → Jun 2027 expected | metabolic dysfunction-associated steatohepatitis | The United Bio-Technology (Hengqin) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07134335 | Sep 2025 → Jul 2030 expected | chronic kidney disease, obesity disorder | The United Bio-Technology (Hengqin) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07163624 | Mar → Nov 2025 | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT07177469 | Mar → Oct 2025 | obesity disorder | The United Bio-Technology (Hengqin) Co., Ltd. | Completed | Met primary |
| Phase 34 trials | ||||||
| Phase 3 | NCT07806851 | Oct 2026 → Mar 2029 expected | obesity disorder, obstructive sleep apnea syndrome | The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07659574 | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07653477 | Sep 2026 → Feb 2028 expected | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07648225 | Jul 2026 → Sep 2027 expected | obesity disorder | The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-25 | Novo Nordisk A/S | Results Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes novonordisk.com ↗ |
| 2026-02-24 | Novo Nordisk A/S | Results Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China novonordisk.com ↗
The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UBT251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07134335 ↗ |
| Route | Subcutaneous | “Patients will be treated with UBT251 s.c. once weekly for 24 weeks.” NCT07134335 ↗ |